Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

Guy Amit; Amit Rosen; Avraham B Wagshal; Dan Y Bonneh; Tzvika Liss; Aviva Grosbard; Reuven Ilia; Amos Katz

doi:10.1016/j.amjcard.2004.02.071

Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

Am J Cardiol. 2004 Jun 15;93(12):1558-60. doi: 10.1016/j.amjcard.2004.02.071.

Authors

Guy Amit¹, Amit Rosen, Avraham B Wagshal, Dan Y Bonneh, Tzvika Liss, Aviva Grosbard, Reuven Ilia, Amos Katz

Affiliation

¹ Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University, Beer Sheva, Israel.

PMID: 15194037
DOI: 10.1016/j.amjcard.2004.02.071

Abstract

The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Anti-Arrhythmia Agents / therapeutic use*
Atrial Fibrillation / drug therapy*
Cohort Studies
Drugs, Generic / therapeutic use*
Emergency Service, Hospital / statistics & numerical data
Female
Humans
Male
Patient Admission / statistics & numerical data
Propafenone / therapeutic use*
Recurrence
Retrospective Studies
Therapeutic Equivalency
Treatment Outcome

Substances

Anti-Arrhythmia Agents
Drugs, Generic
Propafenone